Trial Profile
Asingle-center, retrospective, non-randomized chart review comparing readmission rates for patients who received rivaroxaban or enoxaparin for venous thromboembolism prophylaxis after total hip arthroplasty (THA) or total knee arthroplasty (TKA).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jul 2016
Price :
$35
*
At a glance
- Drugs Enoxaparin sodium (Primary) ; Rivaroxaban (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- 21 Jul 2016 New trial record
- 01 Jun 2016 Results published in the P and T